These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 33684428)
1. Analytical comparability assessment on glycosylation of ziv-aflibercept and the biosimilar candidate. Shen Z; Wang Y; Xu H; Zhang Q; Sha C; Sun B; Li Q Int J Biol Macromol; 2021 Jun; 180():494-509. PubMed ID: 33684428 [TBL] [Abstract][Full Text] [Related]
2. Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping. Lee JY; Choi JW; Hwang S; Hahm SH; Ahn YH Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233110 [TBL] [Abstract][Full Text] [Related]
3. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry. Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062 [TBL] [Abstract][Full Text] [Related]
4. LC-MS/MS peptide mapping with automated data processing for routine profiling of N-glycans in immunoglobulins. Shah B; Jiang XG; Chen L; Zhang Z J Am Soc Mass Spectrom; 2014 Jun; 25(6):999-1011. PubMed ID: 24664809 [TBL] [Abstract][Full Text] [Related]
5. Recombinant human lecithin-cholesterol acyltransferase Fc fusion: analysis of N- and O-linked glycans and identification and elimination of a xylose-based O-linked tetrasaccharide core in the linker region. Spahr C; Kim JJ; Deng S; Kodama P; Xia Z; Tang J; Zhang R; Siu S; Nuanmanee N; Estes B; Stevens J; Zhou M; Lu HS Protein Sci; 2013 Dec; 22(12):1739-53. PubMed ID: 24115046 [TBL] [Abstract][Full Text] [Related]
6. Characterization of glycosylation sites for a recombinant IgG1 monoclonal antibody and a CTLA4-Ig fusion protein by liquid chromatography-mass spectrometry peptide mapping. Bongers J; Devincentis J; Fu J; Huang P; Kirkley DH; Leister K; Liu P; Ludwig R; Rumney K; Tao L; Wu W; Russell RJ J Chromatogr A; 2011 Nov; 1218(45):8140-9. PubMed ID: 21978954 [TBL] [Abstract][Full Text] [Related]
7. Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept. Montacir O; Montacir H; Springer A; Hinderlich S; Mahboudi F; Saadati A; Parr MK Protein J; 2018 Apr; 37(2):164-179. PubMed ID: 29411222 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive N-Glycan Profiling of Cetuximab Biosimilar Candidate by NP-HPLC and MALDI-MS. Liu S; Gao W; Wang Y; He Z; Feng X; Liu BF; Liu X PLoS One; 2017; 12(1):e0170013. PubMed ID: 28072827 [TBL] [Abstract][Full Text] [Related]
9. Efficient Expression of Functionally Active Aflibercept with Designed N-glycans. Keshvari T; Melnik S; Sun L; Niazi A; Aram F; Moghadam A; Kogelmann B; Wozniak-Knopp G; Kallolimath S; Ramezani A; Steinkellner H Antibodies (Basel); 2024 Apr; 13(2):. PubMed ID: 38651409 [TBL] [Abstract][Full Text] [Related]
10. Investigation of Site-Specific Differences in Glycan Microheterogeneity by N-Glycopeptide Mapping of VEGFR-IgG Fusion Protein. Hahm YH; Lee JY; Ahn YH Molecules; 2019 Oct; 24(21):. PubMed ID: 31671706 [TBL] [Abstract][Full Text] [Related]
11. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: Mass spectrometric methods. Reusch D; Haberger M; Falck D; Peter B; Maier B; Gassner J; Hook M; Wagner K; Bonnington L; Bulau P; Wuhrer M MAbs; 2015; 7(4):732-42. PubMed ID: 25996192 [TBL] [Abstract][Full Text] [Related]
12. Mass spectrometry for protein sialoglycosylation. Zhang Q; Li Z; Wang Y; Zheng Q; Li J Mass Spectrom Rev; 2018 Sep; 37(5):652-680. PubMed ID: 29228471 [TBL] [Abstract][Full Text] [Related]
13. Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products. Tan Q; Guo Q; Fang C; Wang C; Li B; Wang H; Li J; Guo Y MAbs; 2012; 4(6):761-74. PubMed ID: 23032066 [TBL] [Abstract][Full Text] [Related]
14. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. Xie H; Chakraborty A; Ahn J; Yu YQ; Dakshinamoorthy DP; Gilar M; Chen W; Skilton SJ; Mazzeo JR MAbs; 2010; 2(4):379-94. PubMed ID: 20458189 [TBL] [Abstract][Full Text] [Related]
15. Characterization of intact glycopeptides reveals the impact of culture media on site-specific glycosylation of EPO-Fc fusion protein generated by CHO-GS cells. Wang Q; Yang G; Wang T; Yang W; Betenbaugh MJ; Zhang H Biotechnol Bioeng; 2019 Sep; 116(9):2303-2315. PubMed ID: 31062865 [TBL] [Abstract][Full Text] [Related]
16. Sialyllactose supplementation enhances sialylation of Fc-fusion glycoprotein in recombinant Chinese hamster ovary cell culture. Lee HM; Kim TH; Park JH; Heo NY; Kim HS; Kim DE; Lee MK; Lee GM; You J; Kim YG J Biotechnol; 2024 Sep; 392():180-189. PubMed ID: 39038661 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry. Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058 [TBL] [Abstract][Full Text] [Related]
19. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. Liu L J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915 [TBL] [Abstract][Full Text] [Related]
20. Multiple enzyme approach for the characterization of glycan modifications on the C-terminus of the intestinal MUC2mucin. van der Post S; Thomsson KA; Hansson GC J Proteome Res; 2014 Dec; 13(12):6013-23. PubMed ID: 25406038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]